Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Some therapies for type 2 diabetes (T2DM) are limited by hypoglycaemia, and this underestimated side effect carries an associated morbidity and financial burden. Large trials that have examined strict glycaemic control and cardiovascular outcomes in T2DM have highlighted the potential harm of exposure to hypoglycaemia in people with coronary heart disease. AREAS COVERED: The responses to, and the morbidity associated with, hypoglycaemia in T2DM are discussed with identification of people most at risk of severe hypoglycaemia. The evidence base for non-pharmacological strategies and the risks of hypoglycaemia associated with various treatment modalities are examined. This review provides the clinician with a rational approach to the selection of different anti-diabetes drugs to minimize the risk of hypoglycaemia. EXPERT OPINION: When managing T2DM, insulin and insulin secretagogues should be used judiciously and glycaemic targets individualized to avoid hypoglycaemia. Incretin mimetics present a lower risk of hypoglycaemia with similar efficacy as traditional agents in treating hyperglycaemia. The potential relationship between hypoglycaemia and precipitation of acute cardiovascular events is a highly topical area of research and may help determine what glycaemic targets are appropriate in people with T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Group based training for self-management strategies in people with type 2 diabetes mellitus
Deakin, T. A., McShane, C. E., Cade, J. E., & Williams, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003417.pub2 · Cited by 862
RetractedBailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189 · cited 1×
“Recent large trials in people with T2DM and established macrovascular disease failed to demonstrate the anticipated benefit of strict glycaemic control in terms of fewer vascular events [3].”
BackgroundDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Physical Activity/Exercise and Type 2 Diabetes
Sigal, R. J., Kenny, G. P., Wasserman, D. H., Castaneda-Sceppa, C., & White, R. D. (2006) · Diabetes Care · doi:10.2337/dc06-9910 · Cited by 949 · cited 1×
“The evidence base for this is limited and relies mainly on clinical consensus [36].”
BackgroundBonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Cited by
Hypoglycemia: The neglected complication
Kalra, S., Mukherjee, J. J., Venkataraman, S., Bantwal, G., Shaikh, S., Saboo, B., Das, A. K., & Ramachandran, A. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117219 · Cited by 255
Lopez, J., Annunziata, K., Bailey, R., Morisky, D. E., & Rupnow, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58813 · Cited by 96
Economic burden of hypoglycemia in patients with type 2 diabetes
Liu, S., Zhao, Y., Hempe, J. M., Fonseca, V., & Shi, L. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.87 · Cited by 37
Sreenan, S., Andersen, M., Thorsted, B. L., Wolden, M. L., & Evans, M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0075-x · Cited by 21
“Clinically, there may be an impression that the lower frequency of hypoglycemia in T2DM means that it is of lesser clinical importance in that type of diabetes; such an interpretation, however, may not adequately characterize the impact of hypoglycemia in T2DM [8, 9, 23].”
BackgroundTschöpe, D., Bramlage, P., Schneider, S., & Gitt, A. K. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115610470 · Cited by 12
Metadata
- Authors
- Noh, R. M., Graveling, A. J., & Frier, B. M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-06-14
- Volume
- 12
- Issue
- 14
- Pages
- 2161-2175
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2095150462
- Cited by
- 36
- References
- 48
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. https://app.cochat.ai/papers/10.1517/14656566.2011.589835
- The paper
- Noh, R. M., Graveling, A. J., & Frier, B. M. (2011). Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2011.589835
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.